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Immunological memorySuccessful T cell priming in early postnatal life that can generate effective long-lasting responses until adulthood is
critical inHIVvaccination strategies because it prevents early sexual initiation andbreastfeeding transmissionofHIV.
A chimeric DNA vaccine encoding p55 HIV gag associated with lysosome-associatedmembrane protein 1 (LAMP-1;
which drives the antigen to theMIIC compartment), has been used to enhance cellular andhumoral antigen-speciﬁc
responses in adultmice andmacaques.Herein,we investigated LAMP-1/gagvaccine immunogenicity in theneonatal
period in mice and its ability to generate long-lasting effects. Neonatal vaccination with chimeric LAMP/gag
generated stronger Gag-speciﬁc immune responses, as measured by the breadth of the Gag peptide-speciﬁc IFN-γ,
proliferative responsiveness, cytokine production and antibodyproduction, all ofwhich revealed activation of CD4+
T cells aswell as the generation of amore robust CTL response compared to gag vaccine alone. To induce long-lived T
andB cellmemory responses, itwas necessary to immunize neonateswith the chimeric LAMP/gagDNAvaccine. The
LAMP/gagDNAvaccine strategy could beparticularlyuseful for generating an anti-HIV immune response in the early
postnatal period capable of inducing long-term immunological memory.Imunodeﬁciência, Faculdade de
dicina Tropical, Prédio II, Av Dr
000, São Paulo, Brazil. Fax: +55
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Pediatric infection with HIV remains a signiﬁcant public health
problem in several developing countries, particularly in Sub-Saharan
Africa, where high HIV-seroprevalence exists among pregnantwomen
and more than 2 million children are living with HIV/AIDS (UNAIDS,
2008). In addition to perinatal HIV-1 transmission, changes in sexual
behavior and drug use are also serious social problems that likely
contribute to the high rate of HIV-1-infected children less than
15 years of age (UNAIDS, 2008). In untreated populations, approxi-
mately 20% of children infected with HIV-1 rapidly progress to AIDS or
death in the ﬁrst year of life (Blanche et al., 1997; Mayaux et al., 1996).
Therefore, there is an emerging need for studies involving anti-HIV
vaccine formulations capable of being immunogenic and eliciting a
long-lasting immune response in the neonatal period and throughout
childhood.The neonate adaptive immune response shows expressive varia-
bility, ranging from high antigen non-responsiveness and denomi-
nated immunological tolerance to fully mature and functioning
responses, and it usually presents susceptibility to viral infections
(Siegrist, 2001; Adkins et al., 2004; Rigato et al., 2009; Sarzotti et al.,
1996; Forsthuber et al., 1996). Several peculiarities contribute to the
relative immaturity of the immune system in the neonatal phase,
including small numbers of lymphoid cells, delayed germinal center
formation on lymphoid organs and functional impairment of T, B and
dendritic cells (DCs). These features result in delayed cellular/
humoral responses of shorter duration and lower peak Ab levels
(Adkins et al., 2004; Rigato et al., 2009; Siegrest, 2001; Adkins, 2003.
In fact, neonatal DCs are not good inducers of Ag-speciﬁc T cell
proliferation due to inadequate expression of costimulatory and MHC
class II molecules and deﬁcient IL-12 production (Pihlgren et al., 2001;
Min et al., 2001; Muthukkumar et al., 2000; Rose et al., 2007).
Furthermore, the neonatal phase is characterized by a Th2-skewed
Ag-speciﬁc immune response (Simpson et al., 2003). Despite all of the
limitations and impairments of the immune system, it has been
shown that when vaccines are administered in ideal conditions,
neonatal mice can generate vigorous adult-like CTL responses rather
than become tolerant (Siegrist, 2007; Brito et al., 2009).
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generating immunity to viral infections in mice by intracellular
pathogens (Siegrist, 2007; Zhang et al., 2002), even in the presence
of inhibitorymaternal antibodies (Martinez et al., 1997; Sedegah et al.,
2003; Capozzo et al., 2006). Usually, antigenic peptides generated after
DNA cell transfection are processed in the antigen presenting cell
(APC) cytoplasm and preferentially presented through MHC class I
molecules (Stevenson, 2004). DNA vaccines in humans were sig-
niﬁcantly less immunogenic according to results obtained from
preclinical studies (Lu et al., 2008). The strengthening of promoters,
enhancers and/or other transcriptional elements in DNA vaccines
(Calarota andWeiner, 2004), including biologically active components
such as chemokines and cytokines encoded in the DNA (Lu et al., 2008;
Cheng et al., 2001), and improving peptide presentation by MHC class
II molecules (Marques et al., 2003; Bennett et al., 1997) are all
strategies that have been used to enhance the immunogenicity of
genetic vaccines.
DNA vaccines encoding chimeric antigens in frame with the
lysosome-associated membrane protein (LAMP) are able to target the
antigen to the MHC class II-rich endosomal/lysosomal compartments
(MIIC) and thereby enhance antigen-speciﬁc immune responses
(Marques et al., 2003; Chikhlikar et al., 2004; Chikhlikar et al., 2006;
de Arruda et al., 2004, 2006). A chimeric DNA vaccine containing the
sequence of the 55 kDa HIV-1 Gag protein (p55Gag) inserted between
the transmembrane and cytoplasmic domains of LAMP-1 (LAMP/gag)
and ﬂanked by the inverted terminal regions of adeno-associated virus
(Chikhlikar et al., 2004; Arruda et al., 2006) has been shown to induce
potent CD4+ and CD8+T cell responses, to increase Ab production and
to lead to a long-lasting immune response in adult BALB/c mice, as
compared to p55gag native DNA (Marques et al., 2003; Chikhlikar et al.,
2006; Arruda et al., 2004, 2006). Furthermore, vaccination of Rhesus
macaques with human LAMP/gag promoted stronger cellular and
humoral anti-Gag responses (Chikhlikar et al., 2006 and Valentin et
al., 2009). In addition, immunization of HLA-DR4 transgenic mice with
immature dendritic cells transfected with LAMP/gag induced HIV Gag-
speciﬁc T cell responses of greater avidity and a broader repertoire,
providing a broadly applicable strategy for the functional activation of T
cell antigens for HIV therapeutic vaccines (Simon et al., 2010).
The chimeric LAMP/gagDNA vaccine could represent a strategy for
overcoming the immunological tolerogenic status of the early life
phase by inducing an immune response in the neonatal period. The
present study was designed to test the hypothesis that the LAMP/gag
DNA chimeric vaccine can prime T and B cells in neonates better than
conventional DNA vaccines. If this approach could bypass the
immunological immaturity in the postnatal period, it could generate
long-lasting cellular and humoral immune responses and anti-HIV
immunity. Here, we show that neonatal immunizationwith LAMP/gag
DNA is better than conventional gag native DNA in generating strong
and T and B cell response at an early age of life and persisting until
adulthood.
Results
Broad Gag-speciﬁc IFN-γ and IgG responses following neonatal
vaccination with LAMP/gag
We analyzed the potential immunogenicity of a LAMP/gag DNA
vaccine in the neonatal period and the duration of its effect after
neonatal priming. It has been previously shown that LAMP/gag DNA
immunization elicits higher anti-Gag immune responses in adult
mice than does the gag DNA vaccine, especially when a prime–boost
schedule of priming with LAMP/gag and boosting with gag is used
(LAMP/gag+gag) (Marques et al., 2003; Chikhlikar et al., 2006; de
Arruda et al., 2004, 2006). To assess the immunogenicity of the chimeric
LAMP/gag DNA vaccine in the early stages of life, the immunization
protocol consisted of priming neonate mice at seven days of age (do)with LAMP/gag, gag or Lamp, boosting 18 days later and evaluating ten
days after the boost. As a positive control, we immunized adult mice
twice intradermally with 50 μg of LAMP/gag and gag plasmids (Arruda
et al., 2004). Studies have shown that the characteristics of the immune
response of a neonate at 7 do is comparable to that of the human
newborn (Siegrist, 2001; Siegrist, 2007). First, the immunogenicity of
the DNA vaccines was evaluated by determining the frequency of
peptide-speciﬁc splenic IFN-γ-producing cells using the ELISPOT assay.
For that purpose, splenic cells from mice immunized during the
neonatal period were stimulated with pools of HIV-1-Gag peptides
(25 pools spanning the entire Gag protein). We also used conventional
ELISA to measure anti-Gag Ab in serum from DNA-vaccinated mice.
Fig. 1A shows that splenic cells obtained from neonatal mice primed
with a relatively lowdose (1 μg) of LAMP/gagDNAvaccine and followed
by a boost with gag DNA vaccine secreted IFN-γ upon stimulation with
Gag peptides in 18 (72%) of 25 pools. Two doses of LAMP/gag (1 μg)
promoted a T cell response in 11peptide pools (44%), while only 6 pools
of peptides (24%) were recognized by neonates immunized with two
doses of gag (1 μg) vaccine (Fig. 1B). The prime–boost schedule LAMP/
gag+gag led to a signiﬁcantly higher number of IFN-γ-secreting cells in
three peptide pools compared to gag immunization, whereas those that
received two doses of LAMP/gag (1 μg) differed by a single peptide pool.
In the next protocol (Fig. 1C), we asked whether increasing the dose of
the DNA vaccine (to 5 μg) would increase the amplitude of Gag peptide
recognition. To test this, we evaluated only LAMP/gag and gag two-dose
schedules (LG+LG and G+G). The 5-μg DNA immunization induced
higher numbers of IFN-γ-secreting cells in mice vaccinated with two
doses of LAMP/gag, generating a signiﬁcant increase for eight peptide
pools when compared to gag immunization (Fig. 1C). Increasing the
chimeric DNA vaccine dose of 1 μg to 5 μg promoted a wider amplitude
of peptide recognition. Themain Gag peptides recognized by class I and
II MHC molecules after adult LAMP/gag and gag immunization were
located in peptide pools containing aa 181–227 (for MHC class I) or aa
241–271 and 281–311 (forMHC class II) based on previous ﬁndings (de
Arruda et al., 2006). Thus, LAMP/gag vaccination elicited greater
numbers of IFN-γ-secreting cells in the aa 181–211 pool containing
the immunodominant class I-restricted epitope AMQMLKETINAAEEA
when compared to gag vaccination. Interestingly, although the adult
mouse immunization schedule was 50 μg per dose, the neonatal LAMP/
gag immunizationwith5 μg seemed to elicit immune responses of equal
or greater magnitude with some peptide pools (Fig. 1D). This ﬁnding
showed that neonatal immunization with the chimeric DNA vaccine
evoked a stronger and wider cellular IFN-γ immune response to Gag
peptides thandid gag vaccination alone and that neonatal chimeric DNA
immunization generated a similar response to adult immunization.
When we assessed the anti-Gag antibody responses elicited by the
neonatal DNA immunization protocols (with 1 or 5 μg of DNA) and
those of adult-immunized mice (50 μg of DNA), we found that
priming with LAMP/gag (1 μg) followed by a gag boost was more
efﬁcient at eliciting anti-Gag IgG (Fig. 2A), composed of IgG2a and
IgG2b, as compared to immunization with two LAMP/gag (1 μg)
doses, which essentially induced anti-Gag IgG1 (Figs. 2A–C). In
neonatal mice immunized with 5 μg of LAMP/gag, the subclass
antibody response was similar to adult LAMP/gag DNA-immunized
mice, inducing anti-Gag IgG1, IgG2a and IgG2b. However, immuniza-
tion with gag (50 μg) elicited only anti-Gag IgG at low levels in adult
mice (Figs. 2A and B). Control neonate and adult mice injected with
plasmid containing only the LAMP-1 gene (L+L) did not generate
either IFN-γ-secreting cells recognizing Gag peptides (data not
shown) or speciﬁc Ab.
Taken together, these ﬁndings show that with low DNA amounts,
the LAMP/gag−gag prime–boost schedulewas sufﬁcient to generate a
comparable immune response to the protocol of two 5-μg doses of
LAMP/gag. Furthermore, chimeric LAMP/gag DNA was better than
conventional gag DNA at eliciting cellular and humoral responses
following neonatal immunization.
Fig. 1. Broad Gag-speciﬁc IFN-γ responses in youngmice after neonatal immunizationwith LAMP/gagDNA vaccine. Neonatal BALB/cmicewere primed at 7 days old (do) and boosted
at 25 dowith LAMP/gag or native gagDNAvaccine. Adultmicewere immunizedwith 50 μg of DNA twice at 20-day intervals. Ten days after the last dose, the number of IFN-γ-secreting
splenocytes was determined by ELISPOT assay upon stimulation with 123 peptides grouped in 25 pools containing 5 peptides, each encompassing the complete p55Gag protein
sequence (15-aa peptides overlapping by 11 residues) (represented by the Y axis: 1–500 aa). (A) One-microgram neonatal prime/boost with LAMP/gag plus gag (LG+G) or gag plus
gag (G+G). (B) One-microgram neonatal prime/boost with only LAMP/gag (LG+LG) or gag (G+G); (C) ﬁve-microgram neonatal prime/boost with LAMP/gag or gag; (D) adult
prime/boostwith 50 μg of LAMP/gag (LG+LG) or gag (G+G). The results presented are themean±SEMof 4–5 experiments, each comprising a pool of spleen cells (2–3mice/group).
Spontaneous spot-forming cells (SFCs)were less than 4 IFN-γ SFC/106; this valuewas subtracted from the stimulated condition and is represented on the X axis, and the peptide pools
are represented by the ordinal Gag protein amino acid numbers (1–500 aa) on the Y axis. A response was considered as positive when the SFC number was higher than 10 IFN-γ SFC/
106 cells. *P≤0.05, **P≤0.01 when compared with gag-immunized mice.
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after neonatal LAMP/gag immunization
Next, we analyzed cytokine production by CD4+ and CD8+ T cells
upon stimulation with Gag H-2d class I or class II-restricted
immunodominant peptides or with p24Gag. The pools containing
the 181–227 aa peptide (MHC class I-restricted epitope) and theFig. 2. Neonatal priming with LAMP/gag DNA vaccine is essential for eliciting anti-Gag IgG an
DNA according to the following the prime–boost schedules: LAMP/gag+gag (LG+G); LAM
were immunized twice with 50 μg of DNA vaccine at 20-day intervals. Anti-Gag antibody le
pools (three pools of nine mice/group, neonate serum dilution, 1:900; adults, 1:2700) ten
compared with gag-immunized mice.241–271 aa and 281–311 aa peptides (MHC class II-restricted
epitope) were recognized when CD4+ or CD8+T cells were depleted,
respectively (Arruda et al., 2006).
Analyzing theprotocol inwhichneonatemicewere immunizedwith
the low dose of DNA (1 μg), we detected a higher number of IFN-γ
secreting cells for the class I-restricted immunodominant epitope in
animals that received one dose of LAMP/gag followed by gag or twotibodies. Neonates were primed at 7 do and boosted at 25 do with 1 and 5 μg of plasmid
P/gag+LAMP/gag (LG+LG); gag+gag (G+G) and LAMP+LAMP (L+L). Adult mice
vels of IgG (A), IgG1 (B), IgG2a (C) and IgG2b (D) subclasses were evaluated in serum
days after the boost by ELISA. Each bar represents the mean±SEM. *P≤0.05 when
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increases were much greater when higher vaccine doses were used
(Fig. 3D). In addition, higher secretion levels of IFN-γ upon class
I-restricted peptide stimulation were detected in the mice immunized
with LAMP/gag+gag, and TNF-α was higher when the mice received
two doses of LAMP/gag compared to gag alone (Figs. 3B and C,
respectively), this similar proﬁle of cytokine production was also
observed in the neonatal immunization protocol using the higher dose
of DNA (5 μg), (data not shown). We then analyzed the number of
IFN-γ-secreting cells from neonatal immunized mice upon stimulation
with GagH-2d class I or class II-restricted immunodominant peptides or
with p24Gag. Vaccination with 5 μg of LAMP/gag DNA promoted a
higher number of IFN-γ-secreting cells recognizing Gag H-2d class I or
class II-restricted immunodominant peptides and p24Gag than did
vaccination with gag DNA alone (Figs. 3D–F). These results show that
LAMP/gag immunization generatedmoreGag-speciﬁc CD8+andCD4+
T cells compared to gag immunization alone.
Next, we assessed the immune responses to neonatal and adult
immunization using two5-μg doses of chimeric LAMP/gag by evaluatingFig. 3. Neonatal priming with LAMP/gag DNA vaccine induced robust CD8+ and CD4+ T c
schedules: LAMP/gag+gag (LG+G, striped bar), LAMP/gag+LAMP/gag (LG+LG, closed ba
boost schedule LAMP/gag+LAMP/gag (LG+LG). (A, D) Splenic IFN-γ-secreting cell
(AMQMLKETINAAEE) were evaluated by ELISPOT (5–8 mice/group). (B) IFN-γ and (C) TNF
72 hwith 10 μg/mL immunodominant GagMHC class I-restricted H-2Kd peptide and evaluat
between the cytokine levels produced after stimulation and spontaneous production. The
recognizing the immunodominant Gag MHC class I and II-restricted H-2d peptides and Gag
neonate (closed bar) or adult (gray bar) immunized with 5 µg of DNA (LG+LG). Each bar r
compared with gag-immunized mice , ***Pb0.001 when compared to adult immunization.the frequency of IFN-γ-secreting cells recognizing H-2d Gag class I and
II-restricted peptides and p24 Gag. Unexpectedly, neonatal immuniza-
tion elicited signiﬁcantly higher numbers of IFN-γ-secreting cells
recognizing Gag MHC class I-restricted peptide and p24 than did adult
immunization (Fig. 3G). For the class II peptides, a similar frequency of
IFN-γ-secreting cells was veriﬁed in both groups of mice. This similarity
was only related to LAMP/gag vaccination, because gag immunization
induced similar IFN-γ responses in neonatal and adult immunization
(data not shown).
Increased CD8+ T and CD4+ T cell function following neonatal
immunization with chimeric vaccine
To evaluate the phenotypic and functional characteristics of
immunodominant CD8+ T cells, we analyzed only the neonatal
immunization protocols using the higher DNA dose (5 μg), because
this dose elicited a response to Gag peptides by IFN-γ-secreting cells
(Fig. 1C) and production of anti-Gag antibody (Fig. 2). We also
included a third neonatal immunization protocol (5 μg) that consistedell responses. Neonates were immunized with 1 or 5 μg in the following prime–boost
r) and gag+gag (G+G, open bar). Adult mice were immunized with 5 μg of the prime–
s recognizing the immunodominant Gag MHC class I-restricted H-2Kd peptide
-α production by splenocytes from neonatally immunized mice (n=5–6) cultured for
ed by ﬂow cytometry using a cytometric bead array. The results represent the difference
dashed line represents the assay detection limit. (D, E, F) Splenic IFN-γ-secreting cells
p24 were evaluated by ELISPOT (5–8 mice/group). (G) Splenic IFN-γ-secreting cells of
epresents the mean±SEM of 4–5 experiments. *P≤0.05, **P≤0.01 , ***Pb0.001 when
41P.O. Rigato et al. / Virology 406 (2010) 37–47of priming with LAMP/gag and boosting with gag. The number of Gag-
speciﬁc CD8+ T cells binding the H-2Kd pentamer bearing the MHC
class I-restricted Gag epitope was estimated following immunization.
Fig. 4A shows that neonatal mice immunized with LAMP/gag+gag
had a signiﬁcantly higher frequency of Gag epitope-speciﬁc CD8+ T
cells (~2.8%) compared to mice immunized with two doses of LAMP/
gag (~1.8%) or gag alone (~1.7%). Moreover, the in vivo CTL response
to the Gag H-2Kd MHC class I-restricted epitope revealed that the
vaccination schedules with LAMP/gag+gag and LAMP/gag+LAMP/
gag improved CD8+ T cell cytotoxic function compared to gag
immunization (Fig. 4B).
The higher CTL response after neonatal LAMP/gag+gag immuni-
zation correlated with higher percentages of CD8+ T cells expressing
LAMP-1 (CD107a) and Granzyme B+ (Fig. 4C). In addition, the greater
frequency of Gag epitope-speciﬁc CD8+ T cells in LAMP/gag+gag
mice than in gag+gag mice was related to the signiﬁcantly higher
number of CD8+IFN-γ+ (Fig. 4D) and CD8+TNF-α+ cells (Fig. 4E).
Despite the fact that neonatal immunization with conventional gag
DNA generated similar percentages of Gag epitope-speciﬁc CD8+ T
cells, these cells had no CTL activity compared to those generated by
neonatal LAMP/gag priming (4B).
Because the LAMP/gag chimeric protein is targeted to class II MHC-
rich cell compartments (Marques et al., 2003),we assessed the CD4+T
cell proliferative response to p24Gag as well as the CD8+ T cell
response to class I-restricted immunodominant Gag peptide by [3H]
thymidine uptake.
To determine which cell population was induced by the neonatal
LAMP/gag and gag DNA immunizations, we evaluated these schedules
using two doses of LAMP/gag or gag. Higher proliferative responses to
MHC class II-restricted Gag peptide and p24Gag were observed in
splenic cells from mice neonatally immunized with LAMP/gag than inFig. 4. Characterization of theCD8+T cell response to neonatal LAMP/gag vaccination.Neonata
(LG+G, striped bar), LAMP/gag+LAMP/gag (LG+LG, closed bar) and gag+gag (G+G, open b
cells for theH-2Kd class I immunodominantGagpeptide. (B) In vivoT cell cytotoxicitywas evalua
dose of DNA vaccines, immunized and non-immunized mice were iv-injected with target cells
target cells were pulsed with class I immunodominant peptide (AMQMLKETI). After 18 h, sple
percentage of lysis. The histogram shows the diminished high-CFSE population in neonatally
expression of granzyme and extracellular expression of LAMP-1 on CD8+T cells by ﬂow cyt
I-restricted peptide overnight for detection of (D) IFN-γ and (E) TNF-α expression in CD8+
when compared to mice immunized with two doses of LAMP/gag.cells from gag-immunized mice (Fig. 5A), suggesting greater CD4+ T
cell stimulation. In addition, neonatal immunization with LAMP/gag
generated higher percentages of CD4+ T cells that proliferated in
response to p24 than did neonatal gag immunization (Fig. 5B),
suggesting enhanced CD4+ T cell activation. Neonatal chimeric DNA
vaccination also enhanced the CD8+ T cell proliferative response to
p24Gag protein (Fig. 5C) as well as to the immunodominant Gag H-2d
MHC class I-restricted epitope (Fig. 5D).
These results show that priming the neonatal immune systemwith
LAMP/gag chimeric DNA vaccine was more effective at generating Ag-
speciﬁc CTLs and at inducing the proliferation of CD4+ T and CD8+ T
cells than was the conventional gag DNA vaccine.
Long-lasting cellular and humoral responses following neonatal LAMP/
gag vaccination
Wenext determinedwhether only neonatal primingwith LAMP/gag
vaccine could induce long-lasting effector cells that secrete IFN-γ after
Gag peptide stimulation. First, neonatal mice were primed with 5 μg of
the DNA vaccine at 7 do and boosted at adult age (six months old) with
5 μg of the sameDNA vaccine. This protocol was used to assesswhether
only the neonatal primingwith LAMP/gag at seven days oldwithout the
boost at 25 days old could induce more IFN-γ-secreting cells at six
months of age than conventional gag immunization.
The results clearly showed that LAMP/gag priming during the
neonatal period led to a higher frequency of IFN-γ-secreting cells
recognizing ten pools of Gag peptides, including MHC class I and II-
restricted peptides, than did conventional gag DNA immunization
(Fig. 6A). In addition, only the mice that were primed during the
neonatal period with LAMP/gag developed high levels of anti-Gag IgG
(Fig. 6B). To verify the importance of the priming during neonatallmicewere immunizedwith 5 μg in the following prime–boost schedules: LAMP/gag+gag
ar). Ten days later, themice were evaluated. (A) Ex-vivo percentage of CD8+pentamer+
ted after theneonatal prime–boostDNA immunizationprotocols. Tendays after the second
from non-immune mice stained with low and high-CFSE concentrations. The high-CFSE
nic cells from immunized and non-immunized (NIm) mice were evaluated to detect the
immunized LG+G and LG+LG mice compared to G+G mice. (C) Ex vivo intracellular
ometry. Splenocyteswere incubatedwith the immunodominant Gag H-2KdMHC class
T cells by ﬂow cytometry. *P≤0.05, **P≤0.01 when compared to gag; and #P≤0.05
Fig. 5. Neonatal LAMP/gag DNA immunization induced greater proliferation of CD8+ and CD4+ T cells than conventional gag DNA immunization. (A) Splenic cells from mice
neonatally immunized with 5 μg in the prime–boost schedules LAMP/gag+LAMP/gag (LG+LG) and gag+gag (G+G) were cultured with Gag MHC class I and II-restricted H-2d
peptides and p24 from HIV-1 for seven days. [3H]thymidine uptake is presented as the stimulation index (SI). (B, C, D) CD4+ and CD8+ proliferation measured by CFSE. Splenic cells
stained with 5 μM CFSE were stimulated with (B, C) 2 μg of HIV p24 or (D) 10 μg of Gag MHC class I H-2d-restricted peptide for six days. CD4+, CD8+ and low-CFSE cells were
analyzed by ﬂow cytometry. *Pb0.05 or **Pb0.05 when compared with gag.
42 P.O. Rigato et al. / Virology 406 (2010) 37–47period, at seven days old, we performed a control experiment in
which groups of mice received priming only (one vaccine dose) at six
months of age. These mice developed fewer IFN-γ-secreting cells
recognizing the Gag MHC class I and II-restricted peptides than did
mice primed at 7 do (Fig. 6C). These results further indicated that
neonatal priming with the chimeric DNA efﬁciently generated IFN-γ
effector memory cells.
To verify the activated/memory phenotype of the CD4+ and CD8+ T
cells after neonatal immunization (at 7 and 25 do), we analyzed the
expression of activation and memory markers and cytokines onFig. 6. Long-lasting T cell and humoral responses after neonatal primingwith chimeric LAMP/
sixmonthswith 25 μg in the following prime–boost schedules: LAMP/gag+LAMP/gag (LG+
γ-secreting cells recognizing 25 pools of Gag peptides were evaluated by ELISPOT. The result
(three mice/group). (B) Anti-Gag IgG (1:900) was determined in serum in six-month-old m
MHC class I and II-restricted epitopes from six-month-old mice neonatally immunized at
#P≤0.05 when compared with mice immunized at 6 months.splenocytes in two situations: ex vivo or after stimulation with Gag H-2d
class I or II-restricted peptides.We evaluated the expression of CD107a, a
marker for cytolytic activity (LAMP-1), CD127 (an IL-7 receptor expressed
inmemoryT cells) andCD69 (early activation). At sixmonths of age,mice
immunized as neonates with LAMP/gag and boosted with gag showed
higher ex vivo percentages of CD8+ T cells co-expressing CD107a and
granzyme than did mice immunized with gag (Fig. 7A), and upon
stimulation with the Gag H-2d class I-restricted epitope, they showed a
slightly higher percentage of CD8+ cells expressing CD69+ (Fig. 7B),
indicating a higher percentage of CD8+ T cells with an early activatedgagDNA. Neonatal mice were primedwith 5 μg of DNA vaccine at 7 do and boosted after
LG, closed bar) and gag+gag (G+G, open bar). (A) Ten days after the boost, splenic IFN-
s presented are the mean±SEM of three experiments, each using a pool of splenic cells
ice neonatally immunized mice by ELISA. (C) IFN-γ-secreting cells recognizing Gag H-2d
7 do and from mice immunized only at 6 months. *P≤0.05, when compared with gag
Fig. 7. Phenotypic features of long-lasting T cell responses elicited by neonatal immunization with chimeric LAMP/gag DNA. Neonates were primed with 5 μg of DNA vaccine at 7 and
25 do in the following prime–boost schedules: LAMP/gag+gag (LG+G), LAMP/gag+LAMP/gag (LG+LG) and gag+gag (G+G), and spleen cells were analyzed after six months.
Splenocytes were evaluated ex vivo to detect (A) intracellular expression of granzyme in CD8+CD107a+ cells. Splenocytes were evaluated upon stimulation with Gag H-2d MHC
class I or II-restricted peptides for six hours to detect extracellular expression of (B) CD8+CD69+; (D) CD4+CD69+CD127+ and to detect intracellular expression of (C) IFN-γ/IL-2
in CD8+ (F) and CD4+ T cells and (E) IFNγ/TNFα CD4+ T cells by four-color ﬂow cytometry. The results represent the mean±SEM of 3–4 animals. *P≤0.05 , **Pb0.01 when
compared to gag-immunized mice.
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and CD4+ T cells to express intracellular IFN-γ/IL-2 (an indicator of
proliferation and activation) and IFN-γ/TNF-α (an indicator of cytotoxi-
city and activation). The immunological memory response to the Gag
MHC class I-restricted peptide revealed higher percentages of CD8+ T
cells co-expressing IFN-γ/IL-2 inmice immunizedwith the chimeric DNA
vaccine than in those immunized with conventional gag, 1.9% versus
0.70% (Fig. 7C). No change in the percentage of CD4+ cells expressing
CD69 was detected in stimulated splenic cells after neonatal immuniza-
tion (Fig. 7D). However, two doses of LAMP/gag generated slightly higher
percentages of CD4+ T cells co-expressing IFN-γ/TNF-α (5.3% versus
0.5%, Fig. 7E) and IFN-γ/IL-2 (2.4% versus 0.6%, Fig. 7F) after stimulation
with Gag MHC class II-restricted peptide than did neonatal gag
immunization. These ﬁndings clearly indicate that when neonatal
mice were immunized with LAMP/gag+gag, only augmented levelsFig. 8. Duration of Gag immune responses generated after neonatal immunization using ch
prime–boost schedules: LAMP/gag+gag (LG+G), LAMP/gag+LAMP/gag (LG+LG) and gag
of Gag peptides were evaluated by ELISPOT. The results presented are the mean±SEM of th
(1:900) was determined in serum at different ages up to nine months of age (270 do) by Eof the CD8+ T cell response were achieved, but when neonates were
immunized only with chimeric vaccine (LAMP/gag+LAMP/gag),
long-lasting CD4+ and CD8+ effector T cells were generated.
Fig. 8A shows that up to nine months after LAMP/gag neonatal
vaccination, broadly higher numbers of IFN-γ-secreting cells recogniz-
ing Gag peptide pools as well as Gag MHC class I and II-restricted
peptides were detected, as compared to after conventional gag
immunization. Curiously, the schedule using two doses of LAMP/gag
vaccine resulted in the recognition of three peptide pools, while the
immunization protocol with one dose of LAMP/gag followed by gag
recognized only one. It was remarkable that the Ab levels detected in
nine-month-oldmice immunizedwith chimeric vaccine did not require
a boost formaintenance (Fig. 8B). In contrast to theﬁndingswith IFN-γ-
secreting cells recognizing Gag, the most efﬁcient production of anti-
Gag IgG Ab was in the group receiving the LAMP/gag+gag scheduleimeric LAMP/gag DNA. Neonatal mice were immunized with 1 or 5 μg in the following
+gag (G+G). (A) At nine months of age, IFN-γ-secreting cells recognizing the 25 pools
ree experiments, each using a pool of splenic cells (three mice/group). (B) IgG anti-Gag
LISA. *P≤0.05, **P≤0.01 when compared to gag.
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not shown) produced no detectable anti-p24 IgG Ab at nine months.
These ﬁndings reinforce the concept that targeting the antigen to the
class II MHC compartment during neonatal vaccination is better at
generating immunological memory and long-lasting T and B effector
functions.
Discussion
The main ﬁnding of our study is that for a DNA vaccine to be
immunogenic enough to provide long-lasting responses after neonatal
immunization in mice, it is important to target the antigen to
compartments containing MHC class II molecules. We achieved this
goal by comparing a chimeric LAMP/gagDNAvaccine to a conventional
gag DNA vaccine. Neonatal immunization using LAMP/gag elicited
broad recognition of HIV-1 Gag MHC class I and II-restricted epitopes
and induced a robust CTL response and CD4+ T cell proliferation
favoring anti-Gag Ab production. These results emphasize the concept
that when the neonatal immune system is adequately stimulated by a
vaccine formulation, it is able to establish an Ag-speciﬁc IFN-γ
response similar in magnitude to that of adult-immunized mice.
Targeting the HIV Gag protein to MIIC compartments in the neonatal
period contributes to the development of improved immune
responses that will last throughout adult life.
The administration of a relatively low dose of LAMP/gag (1 μg) in
BALB/c neonateswas able to signiﬁcantly increase the frequency of IFN-
γ-secreting cells recognizing the immunodominant Gag MHC class I-
restricted H-2d epitope AMQMLKETI197–206 as well as the secretion of
IFN-γ and TNF-α. These cytokines may be involved in the anti-HIV CTL
response (Lichterfeld et al., 2004). In fact, we detected improved levels
of in vivo CTL responses against Gag in mice immunized as neonates
with one or two doses of LAMP/gag. Therefore, the chimeric vaccine
promoted broad recognition of immunodominant Gag MHC class I and
II-restricted epitopes following neonatal immunization. These ﬁndings
emphasize the ﬂexibility of the neonatal immunological response,
which, when adequately stimulated, can induce antigen-speciﬁc
cytotoxic T cells, probably due to competent antigen processing and
presentation by MHC class I molecules of APCs (Gold et al., 2007). The
doses administered in the neonatal DNA immunization protocols were
relatively low compared to other murine neonatal DNA immunization
protocols (Zhang et al., 2002;Martinez et al., 1997; Sedegahet al., 2003).
Considering thehighpropensity for tolerance in the neonatal period, the
low doses used for neonatal immunization may overcome the
tolerogenic effect and evoke an efﬁcient cellular and humoral immune
response.One immunizationprotocol that improved immunogenicity at
the early stage of life was priming with LAMP/gag followed by a boost
with gag, revealing the importance of LAMP/gag in a priming
vaccination scheme, as already demonstrated in adult-immunized in
mice (Arruda et al., 2004). The improvement of the immune response
using the LAMP/gag plus gagneonatal immunization protocolwas likely
due to thegeneration of distinct anddiverseMHCclass I and II-restricted
epitopes,which enabled stronger anti-Gag responses by CD4+and CD8
+ T cells. In fact, the proﬁle of anti-Gag IgG subclasseswas composed of
IgG1 and IgG2a in mice immunized with LAMP/gag+gag (1 μg),
showing activation of both Th2 and Th1 cell subtypes. This protocol
enhanced humoral and cellular responses to HIV, as already demon-
strated after adult immunization (Arruda et al., 2004). On the other
hand, two doses of LAMP/gag (1 μg) triggered only IgG1, and an increase
in the vaccine amount to 5 μg was required to produce a proﬁle similar
to the adult counterpart.
Furthermore, the immunization protocols with chimeric LAMP/
gag vaccine were unique in promoting high anti-Gag IgG Ab levels.
These results strengthen the concept of broad CD4+ T cell
activation with LAMP/gag neonatal immunization, as veriﬁed by
higher CD4+ T cell proliferation in response to Gag protein (p24)
and to MHC class II Gag epitopes, as well as by increasedproinﬂammatory cytokine expression (CD4+IFN-γ+IL-2+). The
mechanism by which this LAMP/gag chimeric DNA vaccine elicits
both humoral and cellular responses to the HIV Gag protein could
have an important role in protecting the host from HIV infection.
The augmented cellular response against Gag, one of the ﬁrst
antigens exposed on HIV-1-infected cell membranes (Sacha et al.,
2007), is considered as a good prognostic indicator for AIDS
evolution in HIV-1-infected children (Buseyne et al., 2002). It is
possible that HIV candidate vaccines that induce an immune
response against this early-expressed and conserved HIV protein,
even before the viral cycle has ﬁnished (Sacha et al., 2007), could
represent important tools for eliminating the cells infected early
and, thereby, could inhibit the spread of virus.
Interestingly, immunizing neonatal mice with LAMP/gag induced a
higher frequency of IFN-γ-secreting cells in response to p24 andH-2dGag
class I-restricted peptide pools than did immunizing adult mice with the
same dose of DNA. It is possible that T cells from the antigen-
inexperienced microenvironment found in the postnatal phase can be
more effectively primed than those from the experienced immune
system, even in speciﬁc pathogen-free conditions. It seems that in the
neonatal period, the trafﬁcking of the chimeric LAMP/gagprotein through
the MIIC compartment rich in MHC class II molecules was important for
promoting epitope recognition by CD4+ T cells and, consequently, for
generating humoral and cellular responses, as reported in adult mice
(Marques et al., 2003; de Arruda et al., 2004). The strategy of the LAMP/
gag construct made it possible to overcome the inadequate expression of
MHC class II and costimulatory molecules on APCs in the neonatal period
(Min et al., 2001), which are typically requirements for the generation of
an efﬁcient adaptive immune response. Several studies in mice and
humans showed that the primary T cell-dependent Ab responses induced
in the neonatal period differ from adult responses (Sigriest, 2001; Adkins
et al., 2004; Rigato et al., 2009). On the other hand, in our study, the
cellular Ag-speciﬁc IFN-γ response was comparable between neonatal
and adult immunization, while Ab production following neonatal LAMP/
gag immunizationwas lower than that followingadult immunization. The
lower Ab production in neonates could be related to neonatal immune
characteristics, such as the high proportion of immature splenic B cells
(IgM IgDlow/−) and negative BCR signaling (Adkins et al., 2004).
Nevertheless, the LAMP/gag vaccine was essential for generating a B cell
memory response, as veriﬁed by the long-lasting humoral response
observed up to nine months of age.
The chimeric vaccine was unique in priming at the neonatal phase,
it led to efﬁcient CD4+ T cell activation (an essential mechanism for
generating long-lasting CD8+ T and CD4+ T effector cells), and at six
months, it led to double-positive intracellular cytokine expression. For
an anti-HIV vaccine that generates strong cellular immune effectors,
such as cytokines, antibodies or CTL generation, avoiding an excess of
immune activation could be optimal for clearing the infection.
Although signiﬁcant increases in CD4+ T cell function (as assessed
by cytokine production and proliferation) and CD8+ effector T cells
followed chimeric DNA immunization, regulatory mechanisms could
also be triggered by the vaccination, and these should be evaluated in
future studies.
Long-lasting immunological memory at the B and T cell level was
veriﬁed up to nine months after neonatal immunization. These results
conﬁrm the ﬁnding obtained with adult mice immunized with the
chimeric DNA vaccine (de Arruda et al., 2004). This reinforces that
memory CD4+ and CD8+ T cells may remain in the absence of antigen
and proliferate tomaintain immunological homeostasis (Amanna et al.,
2006), despite the fact that thepersistence of plasmid in vivoneeds to be
evaluated in this model. Residual plasmid DNA has been detected
months after immunization (Coelho-Castelo et al., 2006). The persis-
tence of antibodies after neonatal LAMP/gag immunization up to nine
months of age could be due to the generation andmaintenance of long-
lived or short-livedplasmacells or to plasmid transcription in long-lived
transfected cells.
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dependent on CD4+ T cell activation; however, the maintenance of
the plasma cells is independent of CD4+ T cells and antigen presence
(Maecker et al., 1998; Dorner and Radbruch, 2007; Chan et al., 2001).
The survival mechanisms of memory B cells and long-lived plasma
cells have not yet been elucidated, but factors such as CXCL-12, IL-6,
BAFF and CD44 seem to be required for, although not essential to,
their survival and maintenance (Cassese et al., 2003). Mice infected
with vesicular stomatitis virus revealed that long-lived plasma cells
were responsible for the permanence of antibodies up to 300 days
after infection (Maecker et al., 1998).
Until now, few DNA vaccine strategies that lack cytokines or
adjuvants have been capable of generating and maintaining long-
lasting cellular and Ab anti-HIV responses when used in neonatal mice.
Further investigations addressing neonatal vaccination with LAMP/gag
DNA vaccine for themaintenance of long-lived plasma cells and the role
of these anti-Gag antibodies are required. Taken together, these results
demonstrate that the chimeric LAMP/gag DNA vaccine is capable of
promoting cellular and humoral anti-Gag responses in the neonatal
period that can last until adulthood. Thus, LAMP/gag given at an early
phase of life could establish an anti-HIV response that lasts until
adolescence and sexual initiation, and thereby, it could prevent
breastfeeding transmission.As a therapeutic strategy, LAMP/gag vaccine
administered at an early phase of neonatal infection could improve the
clearance of infected cells and might delay AIDS progression.
Materials and methods
Plasmids
Eukaryotic expression plasmids were constructed using nucleo-
tides 1–1503 of the HIV-1 HXB2 p55gag gene (genBankTM accession
number KO3455) inserted in the mammalian expression vector pITR
(Kessler et al., 1996; Xin et al., 2003), which contains a cytomegalo-
virus promoter and ITR sequences from adeno-associated virus
ﬂanking the expression elements. The mouse LAMP-1 gene (GenBank
J03881) was also cloned into the same vector. For construction of the
LAMP/gag plasmid chimera, the p55gag gene sequence was inserted
between the luminal domain and the transmembrane/cytoplasmic tail
of LAMP-1, as previously described (Marques et al., 2003; Chikhlikar et
al., 2004, 2006; de Arruda et al., 2004; Arruda et al., 2006; Valentin et
al., 2009). All plasmids were produced by transforming DH5α
Escherichia coli (Invitrogen, Calsbad, CA) and puriﬁed using an
endotoxin-free column (Qiagen Inc., Valencia, CA).
Mice immunization
BALB/c mice, aged 1 or 8–10 weeks old, were purchased from
CEMIB (UNICAMP, Campinas, São Paulo, Brazil) and bred in our own
speciﬁc pathogen-free laboratory's facilities. The São Paulo University
Institutional Animal Care and Use Committee approved all animal
studies.
Neonatal immunization
Seven-day-old mice of both sexes were immunized by the
intradermal (i.d.) route with 1 or 5 μg of the DNA plasmids encoding
either pITR/LAMP/gag (LAMP/gag), pITR/gag (gag) or pITR/LAMP
(LAMP). The mice received a second dose at 25 days of age and were
sacriﬁced ten days later. We used the intradermal route of immuniza-
tion, which has previously been shown to elicit similar immunogenicity
thanwhenmicewere immunized by intramuscular route (Arruda et al.,
2004). Somegroupswereprimedwith LAMP/gagDNAandboostedwith
the gag DNA vaccine. To evaluate the long-term response to neonatal
immunization, some groups of immunized neonates were followed for
six or nine months and boosted with 25 μg of DNA vaccine ten days
before sacriﬁce. Some mice were left untreated.Adult immunization
Female adult mice (6–8 weeks old) received two intradermal
doses of 50 μg or 5 μg of each DNA vaccine at 20-day intervals and
were sacriﬁced 10 days later.
Antibody response
Anti-Gag IgG antibody levels were assessed by enzyme-linked
immunosorbent assay (ELISA) as previously described (Marques et al.,
2003). Brieﬂy, 96-wellmicroplates (Greiner, German)were coatedwith
5 μg/mL of HIVIIIB lysate (ABI, Rockville, MD) or 2 μg/mL of p24Gag
(kindly provided by Prof. Luis Carlos Ferreira, Institute of Biomedical
Sciences, University of São Paulo) and incubated overnight at 4 °C. After
blockingwith PBS+0.5%gelatin for 1 h at 37 °C, theplateswerewashed
three times with PBS and incubated with serial dilution samples for 2 h
at37 °C. Afterwasheswith 0.5%Tween inPBS, theplateswere incubated
with the biotinylated antibodies anti-γ, anti-γ1, anti-γ2a, anti-γ2b or
anti-γ3 (SouthernBiotech, Birmingham, Alabama, USA) for 1 h at 37 °C.
Streptavidin peroxidase (Sigma, St. Louis,MO,USA)was added for 1 h at
37 °C, and the reaction was revealed with tetramethyl benzidine
(Calbiochem Corporation, San Diego, CA, USA). The absorbance was
read at 450 nm in an ELISA microplate reader (Bio-Rad, USA).
Isolation of mononuclear spleen cells
Spleens were obtained aseptically and mashed through cell
strainers (BD Bioscience, CA, USA). Mononuclear spleen cells (MSCs)
were isolated after centrifugation on Ficoll–Hypaque solution (Sigma,
St. Louis, MO, USA). After two washes, the ﬁnal cell pellet was diluted
in RPMI 1640 containing 10% fetal calf serum (FCS, HyCloneIII, Logan,
UT, USA). Viability was greater than 95%.
Gag-speciﬁc IFN-γ ELISPOT assay
Enumeration of IFN-γ-producing splenic T cells was performed by
ELISPOT assay according to themanufacturer's protocol (BD Biosciences
Pharmingen, San Diego, CA, USA). Ninety-six-well microplates with
polyvinylidene ﬂuoride (PVDF) membrane support (Millipore, Bedford,
MA, USA) were incubated with 5 μg/mL of anti-IFN-γ for 18 h at 4 °C.
Next, the plates were washed and blocked with RPMI containing 10%
FCS for 2 h at room temperature. Cells (5×105 cells/well) in RPMI with
1% FCS were distributed in duplicates in microplates in the presence of
medium alone, or hamster monoclonal anti-mouse CD3 (1 μg/mL,
Pharmingen), or 10 μg/mL of HIV-1 Gag epitope restricted to H-2dMHC
class I AMQMLKETINEEAAE197–211, or 10 μg/mL of HIV-1 Gag epitope
restricted to H-2d MHC class II-restricted VDRFYKTLRAEQASQ297–308
epitope (NIH AIDS Research and Reference Reagent Program), or with
2 μg/mL of p24Gag fromHIV-1 orwith 10 μg/mL of 25 pools containing
ﬁve HIV Gag peptides (15-mers of the HIV-1 HXB2gag peptide, with
overlapof11 residues, totaling123peptides andnamedaccording to the
amino acid sequence of Gag), or for 18 h at 37 °C in 5% CO2. After the
washes, the plates were incubated with biotinylated anti-IFN-γ for 2 h
at room temperature. The plates were washed and incubated with
avidin-peroxidase and developed with 3-amino-9-ethylcarbazole sub-
strate (Calbiochem). Spotswerequantiﬁedwith an Immunospot Imager
Analyzer using the software ImmunoSpot 3.2 (CTL ImmunoSpot® S4
Analyzer, C.T.L., Cleveland, OH, USA). The reaction was considered
positive when the number of spot-forming cells (SFCs) was equal to or
higher than 10 SFC/106 cells. All results are expressed as the mean
number of SFCs per 106 MSCs.
Cytokine measurement
Mononuclear spleen cells (MSC)were cultured in 96-wellmicroplates
(Costar, Cambridge, MA) with 10 μg/mL of the MHC class I-restricted
AMQMLKETINEEAAE197–211 epitope from HIV Gag protein (NIH AIDS
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after 72 h and stored at−70 °C. Cytokine quantiﬁcation was conducted
using an Inﬂammation mouse kit (BD Pharmingen) and analyzed in a BD
FACSCalibur cytometer (BD Biosciences, San Jose, CA USA).
Proliferation assay with [3H]thymidine
MSCs were cultured in 96-well microplates (Costar) containing
5 μg/mL of the H-2d MHC class I-restricted AMQMLKETINEEAAE197–
211 or the class II-restricted VDRFYKTLRAEQASQ297–311 epitope from
HIV Gag protein (NIH AIDS Research) or 2 μg of p24Gag at 37 °C in 5%
CO2. Thymidine incorporation was measured on day 6 of the culture,
18 h after being pulsed with 1 μCi [3H]thymidine (GE Healthcare,
Little Chalfont, UK).
Proliferation assay with CFSE
MSCs were stained with 5 μMof CFSE (carboxyﬂuorescein-succinimi-
dyl-ester, e-Bioscience, California, USA) at 37 °C for 30 min, washed twice
with RPMI+10% FCS, adjusted to 1×106 cells/mL and culturedwith 1 μg
of p24Gag or 5 μg of Gag class I epitopeAMQMLKETINEEAAE197–211 for six
days at 37 °C in 5% CO2. After six days, the cells were collected and stained
withmouse anti-CD4 PC5 andmouse anti-CD8 PE and analyzed in a four-
colorﬂowcytometer (EpicsXL, BeckmanCoulter, CA,USA). Aminimumof
100,000 events were analyzed, and the results are expressed as the
percentage of CFSE low/CD4+ and CFSE low/CD8+ cells.
Evaluation of CD4+ or CD8+ T cell responses
After neonatal immunization, micewere sacriﬁced, andMSCswere
collected at 35 days or at the end of the long-term evaluation (6 or
9 months old).
Pentamer staining
MSCswere incubated with PE-conjugated H-2Kd/AMQMLKETI HIV
Gag (MHC Class I pentamers) and FITC-conjugated anti-CD8 (ProIm-
mune, Bradenton, USA) for 30 min. After the washes, the cells were
analyzed using four-color direct ﬂow cytometry (Epics XL, Beckman
Coulter, CA, USA). A minimum of 500,000 events were analyzed, and
the results are expressed as the percentage of pentamer+/CD8+cells.
Extracellular staining
MSCs were cultured for six hours with 5 μg of Gag MHC class I and
II epitope to H-2d. Cells were collected, washed and stained using the
antibodies PerCP-conjugated rat anti-mouse-CD4 and anti-mouse-
CD8, PE-conjugated anti-mouse-CD127 and FITC-conjugated anti-
mouse-CD69 (all purchased from BD Pharmingen) for 30 min at 4 °C
in the dark. After the washes, the cells were analyzed using four-color
direct ﬂow cytometry (Epics XL, Beckman Coulter, CA, USA). A
minimum of 50,000 events were analyzed, and the results are
expressed as the percentage of CD4+ or CD8+ expressing CD69.
Intracellular staining
To evaluate granzyme expression, MSCs were stained using
extracellular markers (PerCP-conjugated anti-mouse-CD8 and FITC-
conjugated anti-mouse-CD107a). To evaluate production of IFN-γ, TNF-
α and IL-2, MSCs were incubated with class I or II Gag epitopes for six
hours, and 10 μg/mL brefeldin A (Sigma) was added after 2 h of
incubation at 37 °C. Next, 5×105 cells were stained with PC5-
conjugated anti-mouse CD8 or anti-CD4 (BD Pharmingen) for 30 min.
After the washes, the cells were ﬁxed with 4% paraformaldehyde for
10 min at 4 °C and incubated with PBS, 0.5% saponin (Sigma) and the
following antibodies: PE-conjugated rat anti-mouse-Granzyme B (e-
Bioscience, San Diego, CA, USA), PE-conjugated rat anti-mouse-IFN-γ,
PE-conjugated rat anti-mouse-IL-2, FITC-conjugated rat anti-mouse-
TNF-α or Ig isotype control rat Ab (all purchased from BD Pharmingen)for 40 min at 4 °C. Fluorescence data for 50,000 events were obtained in
a four-color directﬂowcytometer (EpicsXL, BeckmanCoulter, CA, USA).
The results are expressed as the percentage of CD4+ or CD8+ co-
expressing IFN-γ/TNF-α or IFN-γ/IL-2 or only one of these cytokines.
In vivo analysis of CTL activity
To evaluate CTL activity in vivo, neonatal mice were immunized at
7 days old (do) and 25 do (5 μg), and ten days later, they received the
stained target cells, a modiﬁed version of a previously described protocol
(Valentin et al., 2009). MSCs from non-immunized BALB/c mice were
used as target cells and were stained with high (10 μM) or low (1 μM)
concentrations of carboxyﬂuorescein-succinimidyl-ester (CFSE, Molecu-
lar Probes, USA) in RPMI medium for 30 min at 37 °C in the dark. The
population stainedwith high-concentration CFSEwas pulsedwith 2 μg of
class I peptide AMQMLKETI197–205 for one hour at 37 °C. Target cells with
low and high concentrations of CFSE were washed and mixed at a 1:1
proportion in PBS solution. Approximately 3×107 cells in 200 μL of PBS
were injected i.v. into immunized mice. Splenocytes of immunized mice
were collected after 18 h, and transferred target cells were evaluated
based on high and low intensities of CFSE by ﬂow cytometry. The
percentage of lysis was determined by the following calculation: % of
speciﬁc lysis=100−{[(% of CFSE high cells IM/% of CFSE low cells IM)/
(% of CFSE high cells NI/% of CFSE low cells NI)]×100}. IM=immunized;
NI=non-immunized.
Statistics
Values for all measurements are expressed as means±SEM. Data
from two groups were considered statistically signiﬁcant when the P
value was b0.05 using theMann–Whitney test, whereas three or more
groups were analyzed using the Kruskall–Wallis test with Dunn's
post-test. The data were analyzed in GraphPad Prism 3.0 (GraphPad,
San Diego, California, USA).
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